Author:
Hortobagyi Gabriel N.,Gomez Henry L.,Li Rubi K.,Chung Hyun-Cheol,Fein Luis E.,Chan Valorie F.,Jassem Jacek,Lerzo Guillermo L.,Pivot Xavier B.,Hurtado de Mendoza Fernando,Xu Binghe,Vahdat Linda T.,Peck Ronald A.,Mukhopadhyay Pralay,Roché Henri H.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Ries LAG, Melbert D, Krapcho M et al (2008) Surveillance epidemiology and end results. Available at http://seer.cancer.gov/csr/1975_2005/results_single/sect_01_table.01.pdf . Posted on SEERS website 2008
2. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983
3. Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686–3696
4. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313
5. Bonneterre J, Dieras V, Tubiana-Hulin M et al (2004) Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91:1466–1471
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献